Biosimilars 2021 Year in Review
Fish & Richardson Trademark & Copyright Thoughts
JANUARY 11, 2022
Several other companies have also announced plans to pursue interchangeable status for biosimilar products. The number of development programs enrolled in FDA’s Biosimilar Biological Product Development Program has continued to increase, with 100 biosimilar development programs enrolled as of Q4 of Fiscal Year 2021. Reference Product.
52 
Let's personalize your content